On Mad Money Friday night, Jim Cramer checked in Dr. Clay Siegall, chairman and CEO of Seattle Genetics Inc. , a biotech on the front lines of oncology. Siegall said their drug for metastatic bladder cancer is in its first full quarter of sales and doctors are embracing it as the leading treatment. Siegall was also bullish on Tukysa, the company's breast cancer treatment, which received FDA approval this month for advanced-stage HER2-positive breast cancer.

Allogene (ALLO) reports no revenues for the first quarter of 2020.

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 20.99% and 10.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) beats earnings and sales estimates for the first quarter of 2020. The company withdraws its previously provided outlook for 2020 amid uncertainty related to coronavirus.

Invesco QQQ (QQQ), which tracks the Nasdaq 100 Index, joined the $100 billion club of AUM last week.

Q1 2020 Seattle Genetics Inc Earnings Call

Owl Creek Asset Management increased its stake in wireless-communications firm Anterix, while Paulson & Co. bought more Bausch stock.

SGEN earnings call for the period ending March 31, 2020.

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the presentation of new data from its expanding pipeline of marketed and investigational therapies in the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-31. Thirteen abstracts — including an oral presentation of new data from patients with brain metastases who were part of the pivotal HER2CLIMB trial of TUKYSA™ (tucatinib) in patients with previously treated HER2-positive metastatic breast cancer — will highlight the company’s continued progress in advancing research in cancers that have a significant unmet need.

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the BofA Securities Virtual Health Care Conference 2020 on Tuesday, May 12, 2020 at 11:40 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Does Seattle Genetics (SGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the current conditional marketing authorization for ADCETRIS® (brentuximab vedotin) to include treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL), in combination with CHP (cyclophosphamide, doxorubicin, prednisone). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of peripheral T-cell lymphomas (PTCL), including sALCL. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on March 27, 2020.

Biotech’s shares up more than 140% in past year Continue reading...

Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.

Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA™ (tucatinib) tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast cancer, who have previously received two or more anti-HER2 regimens in any setting, including trastuzumab, pertuzumab and trastuzumab-emtansine (T–DM1).

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the first quarter ended March 31, 2020. The Company also highlighted ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) commercial and development accomplishments, TUKYSA (tucatinib) U.S. Food and Drug Administration (FDA) approval and launch as well as progress with its lead programs to treat cancer.

Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

Seattle Genetics (SGEN) reports narrower-than-expected loss in Q1 while revenues beat estimates.

Celebrations may be in order for Seattle Genetics, Inc. (NASDAQ:SGEN) shareholders, with the analysts delivering a...